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Background: Cost of illness studies are needed to provide estimates for input into cost-effectiveness studies and as
information drivers to resource allocation. However, these studies often do not differentiate costs associated with
the disease of interest and costs of co-morbidities. The goal of this study was to identify the 1-year cost of ischemic
stroke compared to the annual cost of care for a comparable non-stroke group of South Carolina (SC) Medicare
beneficiaries resulting in a marginal cost estimate.
Methods: SC data for 2004 and 2005 were used to estimate the mean 12 month cost of stroke for 2,976 Medicare
beneficiaries hospitalized for Ischemic Stroke in 2004. Using nearest neighbor propensity score matching, a control
group of non-stroke beneficiaries were matched on age, gender, race, risk factors, and Charlson comorbidity index
and their costs were calculated. Marginal cost attributable to ischemic stroke was calculated as the difference
between these two adjusted cost estimates.
Results: The total cost estimated for SC stroke patients for 1 year (2004) was $81.3 million. The cost for the
matched comparison group without stroke was $54.4 million. Thus, the 2004 marginal costs to Medicare due to
Ischemic stroke in SC are estimated to be $26.9 million.
Conclusions: Accurate estimates of cost of care for conditions, such as stroke, that are common in older patients
with a high rate of comorbid conditions require the use of a marginal costing approach. Over estimation of cost of
care for stroke may lead to prediction of larger savings than realizable from important stroke treatment and
prevention programs, which may damage the credibility of program advocates, and jeopardize long term funding
support. Additionally, correct cost estimates are needed as inputs for valid cost-effectiveness studies. Thus, it is
important to use marginal costing for stroke, especially with the increasing public focus on evidence-based
economic decision making to be expected with healthcare reform.
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The economic burden of illness for a disease, such as
acute ischemic stroke (AIS) is usually reported as direct
total healthcare cost incurred over time, and these costs
are only rarely compared to the cost of care for an equally
ill, non-stroke, control group. Therefore the outcome of* Correspondence: simpsona@musc.edu
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reproduction in any medium, provided the orcost of illness studies in stroke often misrepresent costs in
a population that tends to have a great amount of care
costs that are related to comorbidities. The reported costs
of stroke are high, so understanding the difference between
the cost of the stroke and the cost of care for comorbid
conditions is important for fiscal planning, cost-effective-
ness studies, and policy assessment purposes.
The economic burden of stroke is potentially substantial,
since the estimates are likely inflated. Estimates indicated
that in the US stroke related costs reached 73.7 billional Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Carolina (SC) which is known for some of the highest
stroke rates in the US, hospitalization costs from stroke
were estimated at $499 million in 2008 [2] with additional
indirect costs due to loss of wages, productivity and
pre-stroke social roles. Stroke in SC and the remainder
of the US is expected to be exacerbated by the aging
population of baby boomers.
Ischemic stroke accounts for 87% of all strokes, with the
remaining strokes falling into one of the hemorrhagic
categories [1,3]. Interventions to treat acute ischemic
stroke are increasingly being used which could effectively
reduce mortality rates, however, long-term morbidity due
to stroke-related impairments are expected to increase.
Despite Medicare’s attempts to contain costs, the total
cost of stroke and other chronic illness in the US continues
to rise. Some speculate that the cost of treatment after
ischemic stroke will increase as mortality rates decrease
and stroke survivors live longer after stroke with their
stroke-related disabilities [4]. Such speculation is difficult
to confirm or deny because of the significant variability
in cost of illness research models and methods. However,
because stroke-related interventions are likely to facilitate
longer lifespans among those experiencing a stroke and
there has been an increase in the comorbidity in the elderly
population, an understanding of the economics of stroke
is becoming increasingly important. Specifically, under-
standing the marginal cost of stroke, i.e. those costs over
and above normal expected medical care, can serve as a
valuable cost benchmark that can be followed accurately
over time. Furthermore, it is important to know what
proportion of stroke health services is attributable to the
initial hospital admission and rehabilitation, and what
proportion are actually attributable to comorbidities.
Therefore the purpose of this study was to examine the
1-year cost of ischemic stroke, cost of hospital admission,
and rehabilitation services and compare those annual
costs of care to a comparable non-stroke group of South
Carolina (SC) Medicare beneficiaries. It is expected that
the analysis will result in a marginal cost estimate of stroke
itself.
Methods
This research project used marginal cost estimation, also
known as case–control cost comparison, to estimate cost
of care for patients with acute ischemic stroke. Marginal
cost was calculated by estimating the costs of resources
used for care after an index event, using population
based patient-level data, less the cost of a similar patient
population who do not have the illness, over the same
period of time. Arguably, this is one of the more precise
ways to estimate overall cost-of-illness, especially in the
case of stroke where most patients are older and have
many comorbid conditions which tend to increase cost [5].Data
A retrospective longitudinal cohort of patients with a
primary diagnosis of ischemic stroke was extracted from
the SC Medicare hospital discharge Standard Analytic
File (SAF) database that contained data for the years
2003, 2004, and 2005. Medicare is a government funded
health insurance program developed to cover individuals
over age 65. Medicare may also insure individuals under
65 who are disabled or anyone who is diagnosed with
end stage renal disease. All Americans over 65 years of
age are automatically enrolled in Part A Medicare coverage
that provides insurance for hospitalizations at no cost to
the enrollee. Other parts of Medicare coverage are also
available but may require monthly premiums. Beneficiaries’
data were linked from different claims files via encrypted
beneficiary identification numbers at the individual level
and followed longitudinally in two groups.
The stroke and the control cohort were then followed
for the remaining time period of available data up until
either death or 365 days from index date. Where data
was available in the six months prior to the index date for
each cohort, diagnosis coding was used to construct the
Charlson comorbidity Index up until and including index
stroke for each patient. The data used in this study were
provided by the SC Office of Research Services (ORS)
from a state-wide cohort of Medicare participants from
SC which was made available to the researchers as part
of the EXCEED grant (South Carolina EXCEED Project
funded by AHRQ under DUA #16339 EDG#4081) to
examine health disparities in minority populations.Patient selection, settings and exclusions
Patients were selected based on the presence of a primary
diagnosis of AIS via the most consistently accurate and
highly specific ICD-9-CM codes of 434.xx or 436.xx in the
hospital impatient claims file [6]. Patients were excluded if
their index stroke date did not take place in 2004 or if they
had a stroke admission in the six months prior to the
index admission (n = 152 excluded due to previous stroke
in prior 6 months), where data were available. This was
done to try to exclude strokes in our indexed stroke count
that were recent re-stroke admissions. Any patients less
than 65 years of age at the time of the hospital admission
for their index stroke were also excluded because such
patients represent a different subpopulation than traditional
Medicare beneficiaries (n = 575 excluded due to age < 65).
Patients with missing race information were also excluded
because race is important to stroke-related and economic
outcomes (n = 22 due to missing race information). A
cohort of 2,679 Medicare patients with an ischemic
stroke in 2004 were identified and included in the analysis.
A control group was selected using propensity score
matching for comparison from a group of 17,924 potential
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with the exclusion of stroke.
Propensity score matching to control group
Two controls were selected for each stroke case using a
matching scheme based on propensity score (PS) similarity.
PS methods using a greedy-match algorithm with caliper
distance set to a width of 0.1 standard deviations of the
logit of the estimated propensity score and a 1 case to
2 control matching scheme, without replacement, was
used to match cases with controls in the final analytical
data set. Known components related to the risks of having
a stroke were included as covariates in the logistic regres-
sion model [7]. Covariates used in the PS model included
age, gender, race, Charlson comorbidity score, and the
following stroke risk factors (as monitored in billing
records from the six months prior to index study start
date): diabetes, heart failure, heart attack, atrial fibrillation,
and hypertension as well as five interaction terms of
gender by each risk factor. Final model selection was
based on hypothesis testing of balance between groups of
all the covariates included in the propensity score logistic
regression models, model with largest r-square value, and
satisfied reduction of the absolute standardized differences
in means between the matched and unmatched data for
all covariates (<0.25).
Statistical analysis
The marginal cost of stroke-related healthcare and stroke-
related rehabilitation care was defined as the cost of caring
for patients with stroke after index stroke hospital admis-
sion that is over and above the cost of general medical
care in the non-stroke control group over the same time
period. Total Medicare payments and total rehabilitation
services payments were calculated using means and
unadjusted differences between groups were tested using
non-parametric Wilcoxon Scores. The marginal cost of
stroke-related rehabilitation was calculated by subtracting
the average total rehabilitation services payments for the
controls, from the average total rehabilitation services
payments for the stroke cases. Rehabilitation services
were selected based on secondary diagnoses using a series
of ICD-9-CM codes (not shown).
Generalized linear modeling techniques were used to
estimate average annual total Medicare payments for stroke
cases and controls and to test for differences between the
stroke case and control groups. The 1-year marginal cost of
stroke-related healthcare was calculated by subtracting the
estimated total Medicare payments for the controls from
the estimated total Medicare payments for the stroke cases.
To correct for the non-normal distribution of Medicare
costs, gamma distributed generalized linear models using
a logarithmic transformation [8] were analyzed using the
PROC GENMOD module in the SAS statistical software.The use of a gamma distributed generalized linear model
with a log transformed link function has been shown to be
a good method to estimate healthcare cost distributions
that are generally right-skewed, especially when the log
transformed dependent variables do not have heavy tails
or excessive heteroscedasticity such as was found to be
true in these data [9]. This type of model was found to fit
these study data well.
Multicollinearity between covariates was assessed using
Pearson correlation coefficients. No collinearity was found
in these data (all p-values > 0.25). Clinically relevant
variables were used to determine which covariates were
initially included in the models to control for population
differences. Covariate adjustment was used to control for
differences in cost that may be attributed to other factors.
Covariates that were tested for potential confounding in
model estimates of stroke and rehabilitation payments
included age, gender, race, Charlson morbidity score, and
number of days alive in the year after index date. Manual
backwards selection regression methods were used to
decide which covariates remained in the final models using
smallest Akaike Information Criterion (AIC), Bayesian
Information Criterion (BIC) values, change in parameter
estimates, and covariate p-values to judge model fit. Vari-
ables with p-values greater than 0.20 were removed from
the models if the AIC and BIC values became smaller than
in the previous model containing the covariate. All analyses
were performed using SAS statistical software (version 9.2;
SAS Institute, Inc., Cary, NC), and statistical significance
was determined at the 0.05 level. The Medical University
of South Carolina Institutional Review Board approved the
study proposal.
Results
Each of the propensity score matched covariates resulted
in statistically equal groups on known potentially biasing
factors (Table 1). Unadjusted outcomes such as, proportion
receiving any rehabilitation services in the year after index
date and proportion who died in the year after index study
date, were higher in the stroke cohort versus the control
group (p-values <0.0001) (Table 1). The average number of
days alive in the year after index study start date (stroke
date for the stroke cohort and randomly selected 2004
medical bill date for the control group) were higher in
the control group than the stroke group (p-value < 0.0001)
(Table 1).
A plot of the absolute standardized differences in means
(Figure 1) offers a good representation of whether selection
bias of known factors has been reduced by matching on
propensity score [10]. Balance (i.e. reduction in standard-
ized mean differences between stroke cases and selected
controls) for each covariate that was used in the logistic re-
gression model of propensity is improved when differences
are reduced after matching to no greater than 0.25 [11].
Table 1 Demographics and Characteristics of 2004 ischemic stroke patients and Matched controls
Overall 2004 Stroke 2004 Controls
(n = 8928) (n = 2976) (n = 5952) p-value*
Age (Approximate)† 78.2 (±6.8) 78.1 (±6.9) 78.3 (±6.8) 0.14
Male^ 3510 (39.3) 1149 (38.6) 2361 (39.7) 0.33
Caucasian^ 6374 (71.4) 2148 (72.2) 4226 (71.0) 0.24
Charlson morbidity score† 2.1 (±1.7) 2.1 (±1.7) 2.0 (±1.6) 0.10
Receiving rehabilitation^ 2438 (27.3) 1303 (43.8) 1135 (19.1) <0.0001
Died year post-index date^ 1975 (22.1) 967 (32.5) 1008 (16.9) <0.0001
Days alive yr post-index date† 309.1 (±115.2) 279.2 (±136.1) 324.0 (±99.8) <0.0001
Stroke risk factors (prior 6 months)
Diabetes^ 3018 (33.8) 991 (33.3) 2027 (34.1) 0.48
Heart failure^ 2606 (29.2) 851 (28.6) 1755 (29.5) 0.38
Heart attack^ 767 (8.6) 280 (9.4) 487 (8.2) 0.06
Atrial fibrillation^ 2423 (27.1) 832 (28.0) 1591 (26.7) 0.22
Hypertension^ 7512 (84.1) 2476 (83.2) 5036 (84.6) 0.09
†Mean (±SD).
^N (%).
*p-values were calculated using non-parametric Wilcoxon Scores for continuous measures, Chi-square or Fisher’s Exact for categorical measures (as appropriate).
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means for each of the fourteen covariates included in
the propensity model is reduced to less than the 0.25
recommended level after matching, indicating good control
of potential selection bias of known confounders.
Marginal cost of stroke
The estimated average per beneficiary healthcare cost in
the first year after ischemic stroke in 2004 was $27,330
(Table 2). Average estimated healthcare costs in the control
group was significantly lower at $18,276 (p-value <0.0001)
(Table 2). Therefore, the marginal cost of stroke, defined as
the cost of healthcare for an average individual who has






























Figure 1 Standardized Difference of Means of PS Covariates Before acost seen in a similar group who have not suffered a
stroke, was the difference between these group estimates,
or $9,054 (Table 2).
The average cost of rehabilitation after stroke in 2004
was $3,735, significantly more than average rehabilitation
services cost for the controls (p-value <0.0001) (Table 2).
The difference between the rehabilitation costs in these
two groups is the 1-year marginal cost of stroke-related
rehabilitation care, or $2,651 (Table 2). Both the average
total healthcare cost differences and rehabilitation cost
differences are illustrated in Figure 2.
Based on stroke estimates from the current study, 1-year
total healthcare cost to SC Medicare in 2004 of benefi-
ciaries having ischemic stroke was $81,334,080 and totalMatched Data
nd After Matching.
Table 2 Rehabilitation services Medicare costs for 2004 stroke cohort and Matched controls†
Overall 2004 Stroke 2004 Controls
(n = 8928) (n = 5952) (n = 2976) p-value*
Total Medicare payments 21,220 (28267) 27,329 (23913) 18,165 (29745) <0.0001
Estimated total Medicare payments# 27,330 18,276 <0.0001
1-year marginal cost of stroke services $9,054
Total rehabilitation services payments 1,968 (5887) 3,735 (8245) 1,084 (3958) <0.0001
1-year marginal cost of stroke rehabilitation services $2,651
†All payments are in 2004 US$ and are reported as mean (SD); payments have been rounded to the nearest dollar.
*p-values for univariate comparisons were calculated using non-parametric Wilcoxon Scores for continuous measures.
#p-values for estimated payments were calculated using multivariable Log linked Gamma Distributed Generalized Linear Model.
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ischemic stroke was $11,115,360 (Table 3). However, when
considering marginal rather than total cost, the annualized
stroke-related healthcare costs to SC Medicare in 2004
were $26,944,704 (Table 3). This reflects a potential $54.4
million over-estimation of Medicare expenditures that were
not due to ischemic stroke. Similarly, the marginal cost of
stroke-related rehabilitation care in 2004 in SC Medicare
patients having ischemic stroke was $7,889,376, resulting in
a $3.2 million over-estimation if total rehabilitation costs
are quoted (Table 3).
When these 2004 SC Medicare stroke cost estimates
are inflated using the Consumer Price Index for healthcare
services to make 2012 dollar projections, 2012 SC Medicare
annualized stroke-related healthcare and rehabilitation care
costs would be over-estimated by $73.2 million and $4.34
million, respectively [12] (Table 3). When SC stroke rates
and costs estimated in this study are used to predict Medi-
care costs for all US ischemic stroke patients, 2012 total
stroke costs are predicted to be $7.32 billion compared
with 2012 marginal stroke-related healthcare costs of only
$2.42 billion, resulting in an over-estimation of stroke-
related expenditures of $4.89 billion (Table 3). Similarly,Figure 2 One Year Cost of Ischemic Stroke in SC (2004).utilizing total cost instead of marginal cost figures to
predict stroke-related rehabilitation care costs of 2012
Medicare beneficiaries would result in an over-estimate
of $290 million (Table 3).
Discussion
The one-year healthcare costs attributable to ischemic
stroke was examined by calculating the marginal estimated
healthcare Medicare payment difference between a 2004
ischemic stroke cohort and a propensity matched 2004 non-
stroke control group. The estimated marginal 2004 cost
of stroke-related healthcare in the year after ischemic
stroke in SC was $9,054. This amount reflects the differ-
ence between the annualized healthcare cost of the stroke
group of $27,330 less the healthcare costs of the propen-
sity score matched non-stroke control group of $18,276
(p-value <0.0001). Similarly, the 2004 marginal cost of
stroke-related rehabilitation services in the year after
ischemic stroke was $2,651, resulting from a statistically
significant difference between the average annualized
total rehabilitation services cost for the stroke group of
$3,735 and the control group of $1,064 (p-value <0.0001).
The findings clearly demonstrated that the total cost of















Total cost $81.3 M $109.5 M $7,319.3 M $11.1 M $15.0 M $1,000.3 M
Marginal cost $26.9 M $36.3 M $2,424.8 M $7.9 M $10.6 M $710.0 M
Differential $54.4 M $73.2 M $4,894.5 M $3.2 M $4.4 M $290.0 M
*Cost estimates are based on costs and incidence rates using the 2004 Stroke Group from this study and are rounded to the nearest tenth of a million $US dollar.
#The number of 2004 Medicare beneficiaries used to estimate SC costs to Medicare was taken from Kaiser Family Foundation State Health Facts website
(www.statehealthfacts.org, accessed on 05/25/2012).
†2012 $US dollars cost projections were calculated using 2004 estimates inflated by Consumer Price Index series CUUR0000SAM2 annual medical care services
adjustment (Bureau of Labor Statistics).
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the cost of stroke as an illness because the marginal cost of
stroke in this older population is attenuated by healthcare
costs related to comorbidities.
While these amounts are substantial and statistically
significant, they are lower than estimates commonly re-
ported. The most frequently cited estimates are by Taylor,
Davis and colleagues (cited in 559 publications referencing
this research (accessed May 2012)) [13]. Interestingly,
the Taylor study continues to be referenced in the “Heart
Disease and Stroke Statistics—annual update: A report
from the American Heart Association” [14-18], even
though this research is based on 1990 data and does not
benefit from recent improvements to methodology. This
continued referencing is likely the result of no new esti-
mates emerging in the literature using population-based
studies on the cost of stroke.
Further, the authors of the Taylor study estimated the
1990 annual direct cost of ischemic stroke in the 65–74 year
age group to be $17,823 ($35,197 in 2004 dollars) versus
the annual healthcare expenditures for their control group
of $2,825 ($5,579 in 2004 dollars) [13]. The Taylor study
reports the annual direct marginal cost of ischemic stroke
of $14,998 in 1990 dollars ($29,618 in 2004 inflated dollars)
which is much higher than we found in the current
research. Differences between the current research and
that undertaken by Taylor and colleagues in their 1997
publication are likely related to differences in the methods
used to estimate these dollar amounts and constantly
changing healthcare practice patterns.
A significant trend toward shorter hospital average length
of stay has been frequently reported in the literature
which is also indicative of changing practice patterns and
third-party payer reimbursement changes over time [19].
For example, the Taylor study reports that 70% of the
medical costs for the first year after a stroke can be
accounted for by the initial hospitalization [13]; however,
the article does not report the average length of stay. In
the current study, initial hospital costs only account for
35% of the first year of total healthcare costs. This may
reflect the declining length of hospital stays [19-21]. Shorter
length of stay would result in lower first year healthcarecost estimates in later studies, however these reductions
may be counteracted by inflation adjustment over time.
The Taylor et. al. study includes a 5% Medicare sample
of the 1990 US population, while the current study uses
all SC Medicare patients with ischemic strokes in 2004.
Taylor et. al. also used an average cost to charge ratio for
all admissions to estimate stroke costs. Estimates based on
cost to charge ratios for all admissions can skew costs
because stroke costs may not follow general hospital cost
to charge trends. The current research uses actual pay-
ments made by Medicare to the provider and does not
make any assumptions in the costing methods. Also,
the Taylor research used a 1 in 1,000 randomly selected,
non-matched control group from the general US Medicare
population. This practice would likely under estimate
the control groups’ healthcare expenditures because the
average Medicare population is more likely to be healthier
than a control group matched on an equally at-risk
population. This type of matching approach would result
in inflated marginal cost estimates. The current study ad-
dresses the potential selection bias caused by unmatched
controls by using propensity score matching to match
the stroke cases to controls, which results in a more
conservative and reasonable marginal cost estimate. An
added benefit of the matching approach used in the
current study was a reduction in the selection bias of
other unmeasured factors that are correlated with the
known covariates used in this matching algorithm. This
gives confidence that the observational study is well
matched and is unlikely to contain much selection bias.
In a seminal study by Samsa and colleagues, the 2-year
cost and survival after cerebral infarction was estimated
based on 1991 data [21]. This publication, which has been
cited 130 times (accessed May 2012), reports the first year
cost of first ever ischemic stroke in the over 65 Medicare
population as $29,444 (in 1991 dollars) [22]. The Samsa
estimate is very similar to the current study’s 1-year cost
estimate of $27,330, but the current study is based on
2004 Medicare payments while theirs is calculated using
1991 data. The Samsa study estimated total average cost
rather than marginal cost. In 1991 the average length of
hospital stay after acute stroke was considerably longer
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when compared to current practice. Their estimates also
used cost to charge ratio adjusted Medicare charges for all
facility bills, rather than payments, which has an unknown
effect on the costs incurred by Medicare. Thus, the esti-
mates provided by Samsa et. al. are no longer applicable
to the current healthcare system and do not take into
account the cost of the non-stroke care that surviving
stroke patients are likely to incur even if they had not
had a stroke. However, the Samsa study provides valuable
insight to the inflated estimation of costs that result from
reporting total healthcare cost instead of marginal cost of
care, particularly in the group examined in the current
study. That is, older individuals tend to have significant
healthcare costs outside of the particular major illness
being studied, which make it essential to take into account
other costs when estimating the costs attributable to a
single disease.
There are many policy implications related to the use
of inflated estimates for stroke. It is generally believed
that commonly quoted figures related to incidence rates,
prevalence rates, proportional estimates of certain services
and cost estimates are inflated. However, the public,
including those in the research community, continue
to use and report those same numbers. This practice may
negatively affect the allocation of funding for other
important research since there are limited dollars to
support health-related research efforts. Furthermore, when
advocacy and governmental groups quote these inflated
estimates they lose credibility with the public and their
ability to make good policy decisions are diminished. Also,
given the climate of cost-containment in health care,
the accuracy of estimates of total cost of care related to
any particular condition can help providers and funding
groups better plan for resources to provide such care.
Limitations
There are several limitations in the analysis of SC Medicare
claims data. There is an inherent limitation of using admin-
istrative claims to ascertain diagnoses and identify resource
use and costs with complete accuracy, because these data
are not purposely collected for clinical research but are
collected for the distinct purpose of making healthcare
payments. It is possible that signs or symptoms related to
stroke may not have been captured in the claims, and that
ischemic stroke patients not diagnosed with 434.xx and
436.xx ICD-9-CM codes under the primary diagnosis
category would be missed by this analysis. Similarly, the
measurement of rehabilitation and general resource use
in these data depends on the design and implementation of
the Medicare fee-for-service plan and its scope of coverage
which may change over time. Medicare reimbursement
rules and healthcare practice patterns that change over time
may also make these 2004 based results less generalizableto current times. The use of SC estimates from this
research may not be representative of stroke costs and
rehabilitation utilization in other states and in the US
since healthcare practice patterns and costs vary geo-
graphically. In addition, the interpretation of rehabilitation
resource use and the assignment of associated costs are
challenging.
Due to the lack of availability of clinical information in
these claims data, the classification of rehabilitation was
based on the inclusion of specific rehabilitation related
codes in the ten diagnosis code and four procedure coding
columns provided in the data files. Provider billing systems
will often allow for a much longer list of these codes when
interpreting medical records into billing data in the clinical
setting. So it is reasonable to assume that some diagnoses
or procedures related to stroke and rehabilitation would
not be included in the Medicare data.
Conclusions
Using a marginal costing approach to estimate healthcare
costs due to ischemic stroke is important in the Medicare
population compared to using total average costing tech-
niques, in order to accurately attribute healthcare costs to
stroke. Indeed, the average total costing approach may be
expected to inflate the estimated 2004 SC total cost due to
stroke for Medicare patients by $54.4 million, because this
approach ascribes expenditures for comorbid conditions
to stroke. Healthcare policy makers should be wary of
burden of illness estimates that employ average total
costs for patients who may be expected to have substantial
comorbid disease.
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